Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck global human health president

Executive Summary

GE Healthcare Bio-Sciences CEO Peter Loescher becomes Merck's first global human health president effective May 1. Loescher will oversee the company's sales and marketing divisions - U.S. Human Health, Human Health Asia Pacific, Human Health Intercontinental and Merck Vaccines - which previously reported directly to CEO Richard Clark. The global human health president position, created as part of the company's sales restructuring announced in December, is intended to produce greater continuity for customers across different markets (1"The Pink Sheet" Dec. 19, 2005, p. 3)...

You may also be interested in...

Merck Sales Restructuring Sacrifices Physician Detailing To Payer Marketing

Merck's restructuring program is shifting selling and marketing resources away from physician detailing towards payer and patient promotion, CEO Richard Clark indicated during the firm's annual business review in Whitehouse Station, N.J

New COVID Treatments Face FDA, Commercial Barriers Despite Ongoing Need

Sponsors want more endpoint clarity as current state of government pandemic response, along with scientific and regulatory hurdles, is constraining efforts to refill a shrinking COVID medicine cabinet and could create vulnerabilities for future pandemics.

China Planning To Ban Gene Editing Technology Exports

Beijing’s latest proposal to ban gene editing is viewed as a direct response to Washington’s tightening grip over the transfer of US technology to China.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts